Jonakayem Pharma Formulation (OPC) Pvt. Ltd.
CYTARABINE

CYTARABINE

Send Inquiry
Sub Group Generic Formulary Brand Name Dosages Unit In treatment of Adverse Effects Contraiindication Special Precaution Interaction Servings

CYTARABINE Cytosar-U. 1 GM/100 mg/500 mg Vial TREATMENT OF ACUTE LUKAEMIA& REFRACTORY DISEASE 1. Neurotoxicity
2. Malaise
3. Dizziness
4. Headache
5. Conjunctivitis
6. Renal dysfunction
7. Nausea
8. Vomiting
9. Leucopenia
10. Thrombocytopenia
11. Diarrhea
12. Anorexia
13. Anal ulcer
14. Abdominal pain
15. Hepatotoxicity
16. Jaundice
17. Myalgia
18. Bone pain
19. Rash
20. Pruritis
21. Flu like syndrome
22. Hyperurecemia
23. Thrombophlebitis
24. Edema
25. Anaphylaxis
26. Bloody stool
27. Hyper pigmentation
28. Alopecia
29. Sore throat
30. Oesophagitis
31. Rhabdomyolysis
32. Reticulocytopenia
1. Contraindicated in patient with hypersensitivity to the drug 1. Hepatic impairment
2. Renal dysfunction
3. Bone marrow depression
4. Severe infections
5. Monitor patients WBC and platelet count periodically
6. Assess patient`s renal and hepatic function periodically
Radiotherapy & other myelotoxic drugs: Bone marrow depression potentiated.
Digoxin: Decreased serum levels of digoxin. Effect seen even several days after stopping therapy.
Gentamicin & Flurocytosine: Efficacy of both decreased.
Intravenous-
Adult-
For the treatment of leukemia: 75-150mg/metre square /day or 5mg/kg/day for 5 days
For the treatment of refractory disease: 3mg/metre square every 12 hrs for up to 6days
Intrathecal-
Adult-
10 - 30 mg/metre square every 2 to 4 days.